Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-19
2005-07-19
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C544S315000, C544S317000
Reexamination Certificate
active
06919346
ABSTRACT:
Isoxazolone compounds having the generic structure:are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.
REFERENCES:
patent: 5686455 (1997-11-01), Adams et al.
patent: 5776954 (1998-07-01), De Laszlo et al.
patent: WO 95/13067 (1995-05-01), None
patent: WO 97/47618 (1997-12-01), None
patent: WO 99/03837 (1999-01-01), None
patent: WO 00/10563 (2000-03-01), None
patent: WO 00/26209 (2000-05-01), None
patent: WO 01/12621 (2001-02-01), None
Dinarello, C. A., “Interleukin-1”,Reviews of Infectious Diseases, vol. 6, No. 1, pp. 51-95, 1984.
Maini, R. et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial”,The Lancet, vol. 354, pp. 1932-1939, 1999.
Weinblatt, M. E. et al., “A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptors:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate”,The New England J. of Medicine, vol. 340, No. 4, pp. 253-259, 1999.
Pelletier, J.P., et al., “coordinate Synthesis of Stromelysin, Interleukin-1, and Oncogene Proteins in Experimental Osteoarthritis”,Amer. J. of Pathology, vol. 142, No. 1, pp. 95-105, 1993.
Farahat, M.N. et al., “Cytokine Expression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis”,Annals of the Rheumatic Diseases, vol. 52, pp. 870-875, 1993.
Tiku, K. et al., “Articular Chondrocytes Secrete IL-1, Express Membrane IL-1, and Have IL-1 Inhibitory Activity”,Cellular Immunology, Vo.. 140, pp. 1-20, 1992.
Web, G. R., et al., “Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis”,Osteoarthritis and Cartilage, vol. 5, pp. 427-437, 1997.
Westacott, A. F., et al., “Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis”,Osteoarthritis and Cartilage, vol. 8, pp. 213-221, 2000.
McDaniel, M.L., et al., “Cytokines and Nitric Oxide in Islet Inflammation and Diabetes”,Proc. Soc. Exp. Biol. Med, vol. 211, No. 1, pp. 24-32, 1996.
Rankin, E.C.C., et al., “The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Necrosis Factor alpha Antibody (CDP571) in Rheumatoid Arthritis”British J. of Rheumatology, vol. 34, pp. 334-342, 1995.
Stack, W.A., et al., “Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease”,The Lancet, vol. 249, No. 9051, pp. 521-524, 1997.
Han, J., et al., “Regulation of MEF2 by p38 MAPK and Its Implication in Cardiomyocyte Biology”,Trends Cardiovasc Med., vol. 10, No. 1, pp. 19-22, 2000.
Hunter, J.J., et al., “Signaling Pathways for Cardiac Hypertrophy and Failure”,The New England J. of Medicine, vol. 341, No. 17, pp. 1276-1283, 1999.
Behr, T.M., et al., “Sustained Activation of Cardiac P38 Mitogen Activated Protein Kinase in the Development of Heart Failure: Premature Mortality is Abolished by Chronic P38 Inhibition in Rat Model of Cardiac Hypertrophy and Failure”,Basic Science, vol. 102, pp. 289, 2000.
Shimamoto, A., et al., “Inhibition of P38 Mitogen-Activated Protein Kinase Suppresses Interleukin-1β-Expression and Prevents Progression of Cardiac Hypertrophy and Congestive Heart Failure in Rats”,Basic Science, vol. 102, pp. 289, 2000.
Aukrust, P., et al., “Cytokine Network in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy”,Am. J. Cardiol, vol. 83, No. 3, pp. 376-382, 1999.
Singh, A., et al., “Inducible Nitric Oxide Synthase in Vascular Smooth muscle Cells From Prehypertensive Spontaneously Hypertensive Rats”,Am. J. Hypertens., vol. 9, No. 9, pp. 867-877, 1996.
Dinarello, C.A., “Interleukin-1 and Interleukin-1 Receptor Antagonist”,Supplement to Nutrition, vol. 11, No. 5, pp. 492-494, 1995.
Rrenzetti, L.M., “Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways”,Inflammation Research, 46 Suppl. vol. 2, pp. S143-S144, 1997.
Elhage, R. et al., “Differential Effects of Interleukin-1 Receptor antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in apolipoprotein E-Deficient Mice”,Circulation, vol. 97, No. 3, pp. 242-244, 1998.
Howells, G.L., “Cytokine networks in destructive periodontal disease”,Oral Diseases, vol. 1, pp. 266-270, 1995.
Holden, R.J. et al., “The Role of tumor Necrosis Factor-α in the Pathogenesis of anorexia and Bulimia Nervosa, Cancer Cachexia and Obesity”,Medical Hypotheses, vol. 47, pp. 423-438, 1996.
Beisel, W.R., “Herman Award Lecture, 1995: Infection-induced mainutrition-from cholera to cytokines”,Am. J. Clin. Nutr., vol. 62, pp. 813-819, 1995.
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”,Current Medicinal Chemistry, vol. 6, pp. 807-823, 1999.
Foster, M.L. et al., “Potential of p38 Inhibitors in the Treatment of Rheumatoid Arthritis”,Drug News Perspect, vol. 13, No. 8, pp. 488-497, 2000.
Adams, J.L. et al., “Pyrimidinylimidazole Inhibitors of CSBP/P38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes”,Bioorganic&Medicinal chemistry Letters, vol. 8, pp. 3111-3116, 1998.
Clark Michael Philip
De Biswanath
Djung Jane Far-Jine
Laughlin Steven Karl
Natchus Michael George
Balasubramanian Venkataraman
Echler Sr. Richard S.
The Procter & Gamble & Company
LandOfFree
Isoxazolone compounds useful in treating diseases associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoxazolone compounds useful in treating diseases associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazolone compounds useful in treating diseases associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388688